Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A quantitative method for the selective 5-HT2A agonist 25CN-NBOH in rat plasma and brain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Rapid quantification of quinine and its major metabolite (3S)-3-hydroxyquinine in diluted urine by UPLC-MS/MS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Characterization of a liposome-based formulation of oxaliplatin using capillary electrophoresis: encapsulation and leakage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Measurement of lumefantrine and its metabolite in plasma by high performance liquid chromatography with ultraviolet detection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The value of circulating microRNAs for early diagnosis of B-cell lymphoma: A case-control study on historical samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Following intense research efforts, modulation of the immune system has finally proved to be a viable approach for treating malignant disease. Recently, chimeric antigen receptor redirected T cells have achieved promising outcomes in patients with B-cell malignancies and they are currently also being investigated in other haematological malignancies, solid tumours and viral infections. Compared with traditional biopharmaceuticals, the properties of genetically modified chimeric antigen receptor redirected T-cell therapies differ in many aspects, thereby posing challenges in terms of post-authorisation data collection and data analysis. We believe that the network of population-based Nordic healthcare databases has some characteristics that can help provide important data on these new types of advanced products. In particular, the possibility of very long follow-up periods with a limited loss to follow-up is an important strength. Given the limited source population and slow access to data, a Nordic chimeric antigen receptor redirected T-cell monitoring project should be seen as complementary to other surveillance initiatives.

OriginalsprogEngelsk
TidsskriftPharmaceutical Medicine
Vol/bind33
Udgave nummer2
Sider (fra-til)83-88
Antal sider6
ISSN1178-2595
DOI
StatusUdgivet - apr. 2019

ID: 59260737